The single agent efficacy of venetoclax is limited in SCLC because only a very small subset of SCLCs exhibit dependence on BCL-2 expression for survival, while a large subset of SCLC samples exhibit co-dependence on BCL-xL and BCL-2 or MCL-1 [12,13,16]. Here, BCL2L1 is linked to small cell lung carcinoma.